Thyroid GuidePx®: The Papillary Thyroid Cancer treatment guide
Over treatment
Unnecessary radiation exposure from excessive radioactive iodine
Lifelong medication and side effects from removing the entire thyroid
Increased medical costs and recovery time
Under treatment
Cancer recurrence requiring more aggressive treatments later
Potential for cancer to spread to lymph nodes and other areas
Lingering anxiety and stress about your future health
Introducing Thyroid GuidePx®
Setting a new standard
Ready to experience the power of precision medicine?
How it works
Sample collection
A small tumor sample is collected via fine needle aspiration or from a surgical specimen.
Advanced sequencing
The sample is sent to our CAP/CLIA accredited lab, where we perform next-generation sequencing to measure the expression levels of 82 prognostic genes.
Proprietary analysis
Our proprietary algorithm analyzes the genomic data to identify the molecular tumor subtype and potential for aggressive behavior.
Detailed report
You receive a comprehensive report outlining the tumor's key biological features, recurrence risk assessment, and treatment implications.
Why Thyroid GuidePx®?
Accurate risk assessment
By analyzing the expression of 82 genes linked to cancer recurrence, Thyroid GuidePx® identifies the molecular subtype and potential aggressiveness of each patient's tumor with industry-leading accuracy.
Tailored treatment plans
With this detailed risk profile, physicians can confidently tailor treatment intensity based on the individual's specific needs – avoiding overtreatment for low-risk cases.
Comprehensive genomic analysis
Our advanced genomic sequencing techniques combined with machine learning provide an unprecedented view into the tumor's biological behavior.
Proven efficacy
Clinical research shows Thyroid GuidePx® outperforms traditional risk models, with over 96% specificity in identifying low-risk papillary thyroid cancers.
